Journal Scans
High Non-Compliance in the Use of Letrozole After 2.5 Years of Extended Adjuvant Endocrine Therapy. Results From the IDEAL Randomized Trial
The Issue of Non-Compliance With Letrozole in ER+ Breast Cancer
DBY Fontein, JWR Nortier, GJ Liefers, CJH van de Velde Liefers, et al
20120101
2012 Feb 1
Eur J Surg Oncol
High Non-Compliance in the Use of Letrozole After 2.5 Years of Extended Adjuvant Endocrine Therapy. Results From the IDEAL Randomized Trial
Eur J Surg Oncol. 2012 Feb 1;38(2):110-117, DBY Fontein, JWR Nortier, GJ Liefers, CJH van de Velde Liefers, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Aims: The aim of this study was to investigate non-compliance to aromatase inhibitors and factors associated with early treatment discontinuation in the extended adjuvant setting.Methods: The IDEAL trial is a prospective, open-label phase-III trial comparing 2.5 with 5 years of extended adjuvant letrozole (LET) in hormone receptor positive (HRþ) postmenopausal early breast-cancer patients after 5 years of adjuvant endocrine therapy (ET). The purpose of this study was to assess non-compliance in the...
